text:
Abrahamsson, P.A., L.B. Wadstrom, J. Aluments, S. Falkmer, and L. Grimelius. 1987. Peptide-hormone-and serotonin-immunoreactive tumor cells in carcinoma of the prostate. Pathol. Res. Pract. 182:298–307.
Abrahamsson, P.A., S. Falkmer, K. Falt, and L. Grimelius. 1989. The course of neuroendorcrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an endocrine marker. Pathol. Res. Pract. 185:373–380.
Acara, M.A., R.J. Mazurchuk, P.A. Nickerson, and R.J. Fiel. 1991. Magnetic resonance imaging and histopathology of hydronephrosis in the rat. Magnetic Resonanace Imaging 9:89–92.
Akaza, H., S. Kameyama, and Y. Aso. 1987. Significance of tumor markers in the treatment of urological malignancies [in Japanese]. Gan to Kagaku Ryoho 14:3034–3040.
Åkerström, B., and L. Lögdberg. 1990. An intruguing member of the lipwcalin protein family: α1-microglobin. Trends Biochem. Sci. 15:240–243.
Akimoto, S., K. Akakura, and J. Shimazaki. 1988. Prostatic acid phosphatse (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer [in Japanese], Hinyokika Kiyo (Acta. Urol. Jpn.) 34:1389–1396.
al-Abadi, H., and R. Nagel. 1988. Prognostic relevance of ploidy and proliferative activity of renal cell carcinoma. Eur. Urol. 15:271–276.
Alden, C.L. 1986, A review of unique male rat hydrocarbon nephropathy. Toxicol. Pathol. 14:109–111.
Alden, C.L. 1989. Male rat specific alpha2u globulin nephropathy and renal tumorigenesis. Pp. 535–541 in Nephrotoxicity. In Vitro to In Vivo. Animals to Man. P.H. Bach, and E.A. Lock, eds. New York: Plenum Press.
Alden, C.L., and C.H. Frith. 1991. Urinary system. Pp 315 in Handbook of Toxicologic Pathology, W.M. Haschek, and C.G. Rousseaux, eds. San Diego: Academic Press.
Alden, C.L., R.L. Kanerva, G. Ridder, and L.C. Stone. 1984. The pathogenesis of the nephrotoxocity of volatile hydrocarbons in the male rat. Pp. 107–120 in Advances in Modern Environmental Toxicology. Vol. III. Renal Effects of Petroleum
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 227
Biologic Markers in Urinary Toxicology
Abrahamsson, P.A., L.B. Wadstrom, J. Aluments, S. Falkmer, and L. Grimelius. 1987. Peptide-hormone-and serotonin-immunoreactive tumor cells in carcinoma of the prostate. Pathol. Res. Pract. 182:298–307.
Abrahamsson, P.A., S. Falkmer, K. Falt, and L. Grimelius. 1989. The course of neuroendorcrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an endocrine marker. Pathol. Res. Pract. 185:373–380.
Acara, M.A., R.J. Mazurchuk, P.A. Nickerson, and R.J. Fiel. 1991. Magnetic resonance imaging and histopathology of hydronephrosis in the rat. Magnetic Resonanace Imaging 9:89–92.
Akaza, H., S. Kameyama, and Y. Aso. 1987. Significance of tumor markers in the treatment of urological malignancies [in Japanese]. Gan to Kagaku Ryoho 14:3034–3040.
Åkerström, B., and L. Lögdberg. 1990. An intruguing member of the lipwcalin protein family: α1-microglobin. Trends Biochem. Sci. 15:240–243.
Akimoto, S., K. Akakura, and J. Shimazaki. 1988. Prostatic acid phosphatse (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer [in Japanese], Hinyokika Kiyo (Acta. Urol. Jpn.) 34:1389–1396.
al-Abadi, H., and R. Nagel. 1988. Prognostic relevance of ploidy and proliferative activity of renal cell carcinoma. Eur. Urol. 15:271–276.
Alden, C.L. 1986, A review of unique male rat hydrocarbon nephropathy. Toxicol. Pathol. 14:109–111.
Alden, C.L. 1989. Male rat specific alpha2u globulin nephropathy and renal tumorigenesis. Pp. 535–541 in Nephrotoxicity. In Vitro to In Vivo. Animals to Man. P.H. Bach, and E.A. Lock, eds. New York: Plenum Press.
Alden, C.L., and C.H. Frith. 1991. Urinary system. Pp 315 in Handbook of Toxicologic Pathology, W.M. Haschek, and C.G. Rousseaux, eds. San Diego: Academic Press.
Alden, C.L., R.L. Kanerva, G. Ridder, and L.C. Stone. 1984. The pathogenesis of the nephrotoxocity of volatile hydrocarbons in the male rat. Pp. 107–120 in Advances in Modern Environmental Toxicology. Vol. III. Renal Effects of Petroleum
OCR for page 227
Biologic Markers in Urinary Toxicology
Hydrocarbons. M.A. Mehlman, G.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton: Princeton Scientific Publishers, Inc.
Aleo, M.D., and R.G. Schnellman, 1992a. The neurotoxicants strychnine and biculline protect renal proximal tubules from mitochondrial inhibitor-induced cell death. Life Sci. 51:1783–1787.
Aleo, M.D., and R.G. Schnellman. 1992b. Regulation of glycolytic metabolism during long-term primary culture of renal proximal tubule cells. Am. J. Physiol. 262:F77F85.
Aleo, M.D., M.L. Taub, P.A. Nickerson, and P.J. Kostyniak. 1989. Primary cultures of rabbit renal proximal tubule cells: I. Growth and biochemical characteristics. In Vitro Cell. Dev. Biol. 25:776–783.
Alfrey, A.C., and R.C. Tomford. 1982. Phosphate and prevention of renal failure. Pp. 31–38 in Prevention of Kidney Disease and Long-Term Survival, M.M. Avram, ed. New York: Plenum.
Allen, B.C., and J.W. Fisher. 1993. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Analysis 13:71–86.
Allen, B.C., K.S. Crump, and A.M. Shipp. 1988. Correlation between carcinogenic potency of chemicals in animals and humans. Risk Anal. 8:531–544.
Allen, J.K., E.A. Krauss, and E.G. Deeter. 1991. Dipstick analysis of urinary protein. A comparison of Chemstrip-9 and Multistix-10SG. Arch. Path. Lab. Med. 115:34–37.
Allison, M.E., E.M. Lipham, W.E. Lassiter, and C.W. Gottschalk. 1973. The acutely reduced kidney. Kidney Int. 3:354–363.
Almeder, R. and J. Humber. 1987. Introduction to Quantitative Risk Assessment. Biomedical Ethics Reviews, 1986. J. Humbar, R. Almeder, eds. Clifton, N.J.: Humana Press.
Almeida, A.R.P., D. Bunnachak, M. Burnier, J.F.M. Wetzels, T.J. Burke, and R.W. Schrier. 1992. Time-dependent protective effects of calcium channel blockers on anoxia and hypoxia-induced proximal tubule injury. J. Pharmacol. Exp. Ther. 260:526–532.
Ambrose, S.S. 1983. Ureterosigmoidostomy. Pp. 511–520 in Urologic Surgery, 3rd edition, J.F. Glenn, ed. Philadelphia: Lippincott.
Ambrurn, J.L., C.M. Ambrus, P. Forgach, S. Stadler, J. Haplern, S. Sayyid, P. Niswander, and C. Toumbis. 1992. Studies on tumor induced angiogenesis. EXS 61:436–444.
Ames, B.N., and L.S. Gold. 1990. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 249:970–971.
Amico, S., J.C. Liehn, B. Desoize, H. Larbre, G. Deltour, and J. Valeyre. 1991 Comparison of phophotase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. Clin. Nucl. Med. 16:643–648.
Anders, M.W. 1980 Metabolism of drugs by kidney. Kidney Int. 18:636–647.
OCR for page 227
Biologic Markers in Urinary Toxicology
Anders, M.W., ed. 1985. Bioactivation of Foreign Compounds. New York: Academic Press.
Anders, M.W. 1989. Biotransformation and bioactivation of xenobiotics by the kidney. Pp. 81–97 in Intermediary Xenobiotic Metabolism in Animals: Methodology, Mechanisms and Significance. D.H. Hutson, J. Caldwell, and G.D. Paulson, eds. London: Taylor & Francis.
Anders, M.W., L.H. LAsh, W. Dekant, A.A. Elfarra, and D.R. Dohn. 1988 Biosynthesis and metabolism of glutathione conjugates to toxic forms. CRC Crit. Rev. Toxicol. 18:311–341.
Anderson, R.L. 1985. Some changes in gastro-intestinal metabolism and in the urine and bladders of rats in responce to sodium saccharin ingestion. Fd. Chem. Toxic 23:457–463.
Anderson, R.L. 1988. An hypothesis of the mechanism of urinary tumorigenesis in rats ingesting sodium sacchrin. Fd. Chem. Toxic 26:637–644.
Anderson, R.L. 1991. Early indicators of bladder carcinogenesis produced by non-genotoxic agents. Mut. Res. 248:261–270.
Anderson, R.L., and C.L. Alden. 1989. Risk assessment for nitrilotriacetic acid (NTA). Pp. 390–426 in The Risk Assessment of Environmental Hazards. A Textbook of Case Studies. D.J. Paustenbach, ed. New York: John Wiley & Sons.
Anderson, P.M., and M.O. Schultze. 1965. Cleavage of S-(1,2-dichlorovinyl)-L-cysteine by and enzyme of bovine origin. Arch. Biochem. Biophys. 111:593–602.
Anderson, E., and the Carcinogen Assessment Group of the U.S. Environmental Protection Agency. 1983. Quantitative approaches in use to assess cancer risk. Risk Analysis 3:277–295.
Anderson, R.L., W.E. Bishop, and R.L. Campbell. 1985. A review of the environmental and mammalian toxicology of nitrolotriacetic acid. CRC Crit. Rev. Toxicol. 15:1–102.
Anderson, R.L., R.L. Kanerva, F.R. Lefever, and W.R. Francis. 1986a. Effect of N-nitrose-n-butyl-(4-hydroxybutyl)amine exposure on the changes in mineral deposition caused by trisodium nitrilotriacetate. Fd. Chem. Toxic 24:229–235.
Anderson, S., H.G. Rennke, and B.M. Brenner. 1986b. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invset. 7:1993–2000.
Anderson, R.L., F.R. Lefever, and J.K. Maurer. 1988. The effect of various sacchrin forms on gastro-intertinal tract, urine and bladder on male rats. Fd. Chem. Toxic. 26:665–669.
Andersson, G., and E. Jennische. 1988. IGF-I immunoreactivity is expressed by regenerating renal tubular cells after ischaemic injury in the rat. Acta. Physiol. Scand. 132:4653–457.
Andersson, G.L., A. Skottner, and E. Jennische. 1988. Immunocytochemical and
OCR for page 227
Biologic Markers in Urinary Toxicology
biochemical localization of insulin-like growth factor I in the kidney of rats before and after uninephrectomy. Acta. Endocrinol. 119:555–560.
Anglard, P., K. Tory, H. Brauch, G.H. Weiss, F. Latif, M.J. Merino, M.I. Lerman, B. Zbar, and W.M. Linehan. 1991. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res. 51:1071–1077.
Annab, L.A., J.T. Dong, P.A. Futreal, H. Satoh, M. Oshimura, and J.C. Barrett. 1992. Growth and transformation suppressor genes for BHK Syriam hamster cells on human chromosomes 1 and 11. Mol. Carcinog. 6:280–288.
Anonymous. 1985. Acid phosphatases and other tumor markers in the management of prostatic cancer. Proceedings of the Workshop of the Scandinavian Prostatic Cancer Group, Scandinavian Committee on Enzymes. Copenhagen, March 1985. Scand. J. Clin. Lab. Invest. Suppl. 179:1–117.
Anonymous. 1990. Bladder cancer screening in high-risk groups. Proceedings of the International Conference. September 13–14, 1989. J. Occup. Med. 32:787–945.
Arndt, R. J. Durkopf, H. Huland, F. Donn, T. Loening, and H. Kalthoff. 1987. Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells. J. Urol. 137:758–763.
Ash, S.R., and F.E. Cuppage. 1970. Shift toward anaerobic glycolysis in the regererating rat kidney. Am. J. Pathol. 60:385:402.
Askergren, A., L.G. Allgen, and J. Berstrom. 1981. Studies on kidney function in subjects exposed to organic solvents. 1. Excretion of albumin and beta2-microglobulin in the urine. Acta. Med. Scand. 209:479–483.
Askergren, A. 1984. Urinary protein and cell excretion in constructions workers exposed to organic solvents.
Asselin, C., and K.B. Marcus. 1989. Mode of c-myc gene regulation in folic acid-induced kidney regeneration. Oncogene Res. 5:67–72.
Aten, J., C.B. Bosman, J. Rozing, T. Stynen, P. Hoedemacker, and J.J. Weening. 1988. Mercuric chloride-induced autoimmunity in the Brown Norway Rat. Am. J. Path. 133:127–138.
Aulizky, W.K., P.N. Schlogel, D. Wu, C.Y. Cheng, C.C. Chen, P.S. Li, M. Goldstein, M. Reidenberg, and C.W. Bardin. 1992. Measurement of urinary clusterin as an index of nephrotoxicity. Proc. Soc. Exp. Biol. Med. 199:93–96.
Azzopardi, J.G., and D.J. Evans. 1971. Argentaffin cells in prostatic carcinoma: Differentiation from lipofuscin and melanin in prostatic epithelium. J. Pathol. 104:247–251.
Baisch, H., U. Otto, and G. Kloppel. 1986. Malignancy index based on flow cytonetry and histology for renal cell carcinomas and its correlation to prognosis. Cytometry 7:200–204.
Baisch, H., G. Kloppel, and U. Otto. 1990. Pp. 249–260 in DNA analysis in relan neoplasia. New York: Churchill Livingstone.
Balitskaia, O.V., N.K. Berdinskikh, and N.G. Kononenko. 1992. The possibilities of
OCR for page 227
Biologic Markers in Urinary Toxicology
using the free polyamines of the peripheral blood as biochemical tumor markers in nephroblastoma in children [in Russian]. Vopr. Onkol. 38:674–682.
Ballardi, F.W., ed. 1992. Autoimmunity in Nethritis. Chur, Switzerland: Harwood Academic Publishers.
Ballatori, N., R. Jacob, C. Barrett, and J.L. Boyer. 1988. Biliary catabolism of glutathione and differential reabsorption of its amino acids constituents. Am. J. Physiol. 254:G1–G7.
Bander, N.H., C.L. Finstad, C. Cordon-Cardo, R.D. Ramsawak, E.D. Vaughan, W.F. Whitmore, H.F. Oettgen, M.R. Melames, and L.J. Old. 1989. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res. 49:6774–6780.
Bandyk, M., I. Sawczuk, C.A. Olsson, A.E. Katz, and R. Buttyan. 1990. Characterization of the products of a gene expressed during androgen-programmed cell death and their potential use as a marker of urogenital injury.
Banki, K., and M.W. Anders. 1989. Inhibition of rat kidney mitochondrial DNA, RNA and protein synthesis by halogenated cystein S-conjugates. Carcinogenesis 10:767–772.
Baretton, G., B. Kuhlmann, R. Krech, U. Lohrs. 1991. Intratumoural heterogeneity of nuclear DNA-content and proliferation in clear cell type carcinomas of the kidney. Virchows Arch B: Cell Pathol. Mol. Pathol. 61:57–63.
Baricordi, O.R., A. Sensi, C. DeVinci, L. Melchorri, G. Fabris, E. Marchette, F. Corrado, P.L. Mattiuz, and G. Pizza. 1985. A monoclonal antibody to human transitional cell carcinoma of the bladder cross reaction with a differentiation antigen of neutrophilic lineage. Int. J. Cancer 35:781–786.
Barrett, J.C., and J.E. Huff. 1991. Cellular and molecular mechanisms of chemically induced renal cancinogenesis in nephretoxicity. Pp. 287–306 in Mechanisms, Early Diagnosis, and Therapeutic Management . P.H. Bach, N.J. Gregg, M.F. Wiks, and L. Delactuz, eds. New York: Marcel Dekker, Inc.
Balslov, J.T., and H.E. Jorgensen. 1963. A survey of 499 patients with acute anuric renal insufficience. Causes, treatment, complications, and mortality. Am. J. Med. 34:75.
Bass, R.A., G. Hemstreet, N.A. Honker, R.E. Hurst, R.S. Doggett. 1987. DNA cytometry and cytology by quantitative fluorescence inage analysis in sympltomatic bladder cancer patients. Int. J. Cancer 40(5):698–705.
Basta, M.T., A.M. Attallah, M.N. Seddek, H. el-Mohamady, E.S. Al-Hilaly, N. Atwaan, and M. Ghoneim. 1988. Cytokeratin shedding in urine: A biological marker for bladder cancer? Br. J. Unol. 61:116–121.
Bauer, H.W. 1988. Acid phosphatase, alkaline phosphatase and prostate-specific antigen—usefulness in the diagnosis of netastatic disease and follow-up. Prog. Clin. Biol. Res. 269:33–42.
Bauer, D., Müller, J. Reich, H. Riedel, V. Ahrenkiel, P. Warthoe, and M. Strauss.
OCR for page 227
Biologic Markers in Urinary Toxicology
1993. Indentification of differentially expressed mRNA species by an improver display technique (DDRT-PCR). Nucleic Acids Res. 21:4272–4280.
Beckett, M.L., G.B. Lipford, C.L. Haley, P.F. Schellhammer, and G.L. Wright. 1991. Monoclonal antibody PD41 recognizes and antigen restricted to prostate adencarcinomas. Cancer Res. 51:1326–1333.
Beer, D.G., K.A. Zweifel, D.P. Simpson, and H.C. Pitot. 1987. Specific gene expression during compensatory renal hypertrophy in the rat. J. Cell Physiol. 131:29–35.
Beggard, I., and A.G. Bearn. 1968. Isolation and properties of a low molecular weight β2-globulin occuring in human biological fluids. J. Biol. Chem. 243:4095–4103.
Bethrens, M.T., A.L. Corbin, and M.K. Hise. 1989. Epidermal growth factor receptor regulation in rat kidney: Two models of renal growth. Am. J. Physiol. 257:4095–4103.
Beirne, G.J., J.T. Brennan. 1972. Glomerulonephritis associated with hydrocarbon solvents. Arch. Environ. Health 24:365–369.
Bell, G.M., D. Doig, D. Thompson, J.L. Anderton, and J.S. Robson. 1985. End-stage renal disease associated with occupational exposure to organic solvent. Proc EDTA-ERA 22:725–729.
Bell, G.I., N.M. Fong, M.M. Stempien, M.A. Wormsted, D. Caput, L. Ka, M.S. Urdea, L.B. Rall, and R. Sanchez-Pescador. 1986. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res. 14:8427–8446.
Ben-Aissa, H., S. Paulie, and H. Koho. 1985. Specificities and binding properties of two monoclonal antibodies against carcinoma cells of the human urinary bladder. Br. J. Cancer 52:65–72.
Bennett, W.M., L.W. Elzinga, and G.A. Porter. 1991 Tubulointerstitial disease and toxic nephropathy. Pp. 1430–1496 in the Kidney. B.M. Brenner, F.C. Rector, and W.B. Saunders, eds. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo.
Bennington, J.K., and J.B. Beckwith. 1975. Tumors of the Kidney, Renal Pelvis, and Ureter. Pp. 93–199 in Atlas of Tumor Pathology. Second Series, Fascicle 12. Washington, D.C.: Armed Forces Institute of Pathology.
Benson, M.C., I.S. Whang, C.A. Olsson, D.J. McMahon, And W.H. Cooner. 1992a. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 147:813–821.
Benson, M.C., I.S. Whang, A. Pantuckk, K. Ring, S.A. Kaplan, C.A. Olsson, and W.H. Cooner. 1992b. Prostate specific antigen density: A means of distinuishing benign prostatic hypetrophy and prostate cancer. J. Urol. 147:815–816.
Bergerheim, U., M. Nordenskjold, and V.P. Collins. 1989. Deletion mapping in human renal cell carcinoma. Cancer Res. 49:1390–1396.
Bergerheim, U.S., K. Kunimi, V.P. Collins, and P. Ekman. 1991. Deletion mapping of
OCR for page 227
Biologic Markers in Urinary Toxicology
chromosomes 8, 10, and 16 in human prostatic cancinoma. Genes Chromosom. Cancer 3(3):215–220.
Berggard, I. 1970. Plasma proteins in normal human urine. Pp. 7–19 in Proteins in Normal and Pathological Urine. Y. Manuel, J.P. Revillard, and H. Betuel. eds. S. Karger, Basel.
Berlyne, G.M. 1984. Toxic nephropathies and current methods for early dection of the toxicity of the kidney. Pp. 173–184 in Renal Effects of Petroleum Hydrocarbons. Advances in Moderm Environmental Toxicology, Vol. VII. M.A. Mehlman, C.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton: Princeton Scientific Publishers.
Berman, J., J. Seidman, R. Yetter, adn G. Moore. 1991. Clear cell dysplasia of the bladded. Report of a case with flow cytometric analysis. Anal. Quant. Cytol. Histol. 13(6):391–394.
Bernard, A., A. Vyskocyl, P. Mahieu, and R. Lauwerys. 1988. Effect of renal insufficiency on the concentration of free retinol-binding protein in urine and serum. Clin. Chim. Acta. 171:85–93.
Bernard, A.M., R.R. Lauwerys, A. Nöel, B. Vandeleene, and A. Lambert. 1989. Urine protein 1: A sex dependent marker of tubular or glomerular dysfunction. Clin. Chem. 35:2141–2142.
Berndt, W.O. 1981. Use of renal function tests in the evaluation of nephrotoxic effects. Pp. 1–29 in Toxicology of the Kidney, J.B. Hook, ed. New York: Raven.
Berrozpe, G., R. Miro, M.R. Caballin, J. Salvador, and J. Egozcue. 1990. Trisomy 7 may be a primary change in noninvasive transitional cell cancinoma of the bladded. Cancer Genet. Cytogenet. 50:9–14.
Bertani, T., M. Livio, D. Maconi, M. Morigi, G. Bisogno, C. Patrono, and G. Remuzzi. 1987. Platelet activating factor (PAF) as the mediator of injury in nephrotoxic nephritis. Kidney Int. 31:1248–1256.
Bi, W., J.Y. Rao, G.P. Hemstreet P. Fang. N.R. Asal, M. Zang, K.W. Min , Z. Ma, P. Fang, E. Lee, G. Li, R.E. Hurst, W. Wu, R.B. Bonner, Y. Wang, Y. Fradet, and S. Yin. 1993. Field molecular epidemiology: Feasibility of monitering for the malignant bladder cell phenotype in a benzidine exposed occupational cohort. J. Occup. Med. 35(1):20–27.
Birk, H.W., S. Piberhofer, G. Schutterle, W. Haase, J. Kotting, and H. Koepsell. 1991. Analysis of Na+-D-glucose cotransporter and other renal brush border proteins in human urine. Kidney Int. 40:823–837.
Blais, A., F. Jalal, P. Crine, J. Paiement, and A. Bertloot. 1992. Increased functional differentiation of rabbit proximal tubule cells cultured in glucose-free media. Am. J. Physiol. 263:F152–F162.
Blay, J.Y., S. Negrier. V. Combaret, S. Attali, E. Goillot, Y. Merrouche, A. Mercatello, A. Ravault, J.M. Tourani, J.F. Moskovtchenko, T. Phillip, and M. Favrot. 1992.
OCR for page 227
Biologic Markers in Urinary Toxicology
Serum level of interieukin 6 as a prognosis factor in metastatic renal cell cercinoma. Cancer Res. 52:3317–3322.
Blouin, P., M.C. Guiot, and S. Jothy. 1989. Definition of the human renal cell carcinoma phenotype using monoclonal and polyclonal antibodies: A tumor marker study. Exp. Pathol. 36:147–163.
Boag, A.H., and I.D. Young. 1992. Type IV collagenase expression in prostatic adenocarcinoma [abstract]. Mad. Pathol. 5:51A.
Bodenstab, W., J. Kaufman, and C.L. Parsons. 1983. Inactivation of antoadherence effect of bladder surface glycusaminoglycan by a complete urinary carcinogen (N-methyl-N-nitrosourea). J. Urol. 129.
Boehm, T., I. Lavenir, A. Forster, R.B. Wadey, J.K. Cowell, J. Harbott, F. Lampert, J. Waters, P. Sherrington, and P. Couillin. 1988. The T-ALL specific t(11;14)(p13;q11) translocation breakpoint cluster region is locatid near tho the Wilms'tumour prodisposition locus. Oncogene 3:691–695.
Boileau, M., D. Swartz, K. Schmidt, and W. Schmidt. 1987. Bladder cancer dection and surceillance: Carcinoembryonic antigen as a monitor of newplastic transformation. J. Surg. Oncol. 35:120–123.
Boldog, F., K. Arheden, S. Imreh, B. Strombeck, L. Szekely, R. Erlandsson, Z., Marcsek, J. Sumegi, F. Mitelman, and G. Klein. 1991. Involvement of 3p deletions in sporatic and hereditary forms of renal cell cancinoma. Genes Chromosomes Cancer 3:403–406.
Bombassei, G.J., and A. E. Kaplan. 1992. The association between hydrocarbon exposure and antiglomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am. J. Indust. Med. 21:141–153.
Bonner, R.B., G.P. Hemstreet, Y. Fradet, J.Y. Rao, K.W. Min, and R.E. Hurst. 1993. Bladder cancer risk assessment with quantitative fluoroscence image analysis of tumor markers in exfoliated bladder cells. Cancer 72:2461–2469.
Boogaard, P.J., J.N.M. Commandeur, G.J. Mulder, N.P.E. Vermeulen, and J.F. Nagelkerke. 1989. Toxicity of cystein S-conjugates and mercapturic acids of four structurally related difluoroethylenes in isolated proximal tubular cells from rat kidney: Uptake of the conjugates and activation to toxic metabolites. Biochem. Pharmacol. 38:3731–3741.
Boogaard, P.J., J.P. Zoeteweij, T.J.C. van Berkel, J.M. van't Noorkende, G.J. Mulder, and J.F. Nagelkerke. 1990. Primary culture of proximal tubular cells from normal rat kidney as an in vitro model to study mechanisms of nephrotoxicity: Toxicity of nephrotoxicants at low concentrations during prolonged exposure. Biochem. Pharmacol. 39:1335–1345.
Bookstein, R., D. MacGrogan, S.G. Hilsenbeck, F. Sharkey and D.C. Allred. 1993. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:3369–3373.
Borghoff, S.J., B.G. Short, and J.A. Swenberg. 1990. Biochemical mechanisms and
OCR for page 227
Biologic Markers in Urinary Toxicology
pathobiology of α2u-giobulin nephropathy. Ann. Rev. Pharmacol. Toxicol. 30:349–367.
Borghoff, S.J., A.B. Miller, J.P. Bowen, and J.A. Swenberg. 1991 Characteristics of chemical binding to α2u-globulin in vitro—evaluation structure-activity relationships. Toxicol. Appl. Pharmacol. 107:228–238.
Borland, R., C. Brendler, and W.B. Isaacs. 1992. Molecular biology of bladder cancer. Hematol. Oncol. Clin. NorthAm. 6(1):31–39.
Bortz, J.D., P. Rotwein, D. DeVol, et al. 1988. Focal expression of insulin-like growth factor I in rat kidney collection duct. J. Cell Biol. 107:811–819.
Bostwick, D.G. 1989. The pathology, of early prostate cancer. Cancer J. Clin. 39:376–393.
Bostwick, D.G, 1989. Varients of prostatic carcinoma. Pp. 95–133 in Pathology of the Prostate, D.G. Bostwick, ed. New York: Churchill Livingstone.
Bostwick, D.G., Graham, P. Napalkov, P.A. Abrahamsson, P.A. di Sant'Agnese, F. Algaba, P.A. Hoisaeter, F. Lee, P. Littrup, and F.K. Mostofi. 1993. Staging of early prostate cancer: A proposed tumor volume-based prognostic index. Urology 41:403–411.
Boswell, J.M., M.A. Yui, D.W. Burt, and V.E. Kelley. 1988. Increased tumor necrosis factor and IL-1β gene expression in the kidneys of mice with lupus nephritis. J. Immunol. 141:3050–3054.
Bot, F.J., J.C. Godschalk, K.K. Krishnadath, T.H. van der Kwast, and F.T. Bosman. 1994. Prognostic factors in renal-cell carcinoma: Immunohistochemical detection of p53 protein versus clinico-pathological paramenter. Int. J. Cancer 57:634–637.
Boucher, A., D. Droz, E. Adafer, and L-H. Noël. 1986. Characterization of mononuclear cellsubsets in renal cellular interstitial infiltrates. Kidney Int. 29:1043–1049/
Boffioux, C.R. 1980. Etiological and epidemiological considerations in prostatic cancer. Scand. J. Urol. Nephrol., Suppl. 55;9–16.
Bowers, M.A., L.D. Aicher, H.A. Davis, and J.S. Woods. 1992. Quantitative determination of porphyrins in rat and human urine and evaluation of urinary porphyrin profiles during mercury and lead exposures. J. Lab. Clin. Med. 120:272–281.
Boyce, N.W. P.G. Tipping, and S.R. Holdsworth. 1989. Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int. 35:778–782.
Boyle, E. 1970. Biological patterns in hypertension by race, sex, body weight and skin color. JAMA 213:1637–1643
Brady, H.R. B.C. Kone, M.E. Stromski, M.L. Zeidel, G. Giebisch, and S.R. Gullans. 1990, Mitochondrial injury: An early event in cisplatin toxicity to renal proximal tubules. Am. J. Physiol. 258:F1181–F1187.
Brauch, H. K. Tory, W.M. Linehan, D.J. Weaver, M.A. Lovell, and B. Zbar. 1990.
OCR for page 227
Biologic Markers in Urinary Toxicology
Molecular analysis of the sort arm of chromosome 3 in five renal oncocytomas. J. Urol. 143:622–624.
Braver, D.J., M. Modan, A Chetrit, A. Lucky, and Z. Braf. 1987. Drinking, micturition habits, and urine concentration as potential risk factors in urinary bladder cancer. J. Natl. Cancer Inst. 78:437–440.
Brazy, P.C., L.J. Mandel, S.R. Gullans, and S.P. Soltoff. 1984. Interactions between phosphate and oxidative metabolism in proximal renal tubules. Am. J. Physiol. 247:F575–F581.
Brenner, B.M., and S. Anderson. 1989. Filtration surface area, salt intake, and hypertension. Pp. 45–59 in The Progressive Nature of Renal Disease: Myths and Facts. Contributions in Nephrology, Vol. 75, L. Oldrizzi, G. Maschio, and C. Rugiu, eds. Basel: Karger.
Brenner, B.M., and F.C. Rector, eds. 1986. The Kidney, 3rd edition. Philadelphia: W.B. Saunders Company.
Brenner, B.M., T.W. Meyer, and T.H. Hostetter. 1982. Dietary protein intake and the progressive nature of kidney disease. N. Engl. J. Med. 307:652–659.
Bretton, P.R., A. Myc, C. Cordon-Cardo, P. DeAngelis, W.R. Fair, and M.R. Melamed. 1989. Initial evaluation of a new epithelial antigen (TI 6) for bivariate flow cytometry of bladder irrigation specimens. Cytometry 10:339–344.
Breysse, P., W.G. Couser, C.E. Alpers, K. Nelson, L. Gaur, and R.J. Johnson . 1994. Membranous nephropathy and formaldehyde exposure.
Bringuier, P.P., R. Umbas, H.E. Schaafsma, H.F.M. Karthaus, F.M. J. DeBruyne, and J.A. Schalken. 1993. Decreased e-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 53:3241–3245.
Bringuier, P.P., R. Bouvier, N. Berger, E. Piaton, J.P. Revillard, P. Perrin, and M. Devonec. 1993. DNA ploidy status and DNA content instability within single tumors in renal cell carcinoman. Cytometry 14:559–564.
Brochard, P., J. DePalmas, M. Martini, M. Bondet, and G. Largue. 1984. Etude de la prevalence des proteinuries dipistees chex des sujets exposes professionnellment aux solvants. XXI Int. Congr. Occup. Health, Dublin.
Broder, L.E., B.D. Weintraub, S.W. Rosen, M.H. Cohen, and F. Tejada. 1977. Placental proteins and their subunits as tumor markers in prostatic carcinoma. Cancer 40:211–216.
Brooks, D.E. 1987. The major androgen-regulated secretory proteins of the rat epidiymis bear sequence homology with members of the α 2u-globulin superfamily. Biochem. Int. 14:235–240.
Brooks, J.D., G.S. Bova, F.F. Marshall, and W.B. Isaacs. 1993. Tumor suppressor gene allelic loss in human renal cancers. J. Ruol. 150:1278–1283.
Bruner, R.H. 1984. Pathologic findings in laboratory animals exposed to hydrocarbon fuels of military interest. Pp. 133–140 in Advances in Modern Environmental Toxicology. Vol. Vii. Renal Effects of Petroleum Hydrocarbons. M.A. Mehlman,
OCR for page 227
Biologic Markers in Urinary Toxicology
G.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton: Princeton Scientific Publishers, Inc.
Bucher, N.L.R., and R.A. Malt. 1971. Regeneration of liver and kidney. Boston: Little, Brown.
Buchet, J.P., R. Lauwerys, H. Roels, A. Bernard, P. Bruaux, F. Claeys, G. Ducofere, P. De Plaen, J. Staessen, A. Amery, P. Lijnen, L. Thijs, D. Rondia, F. Sartor, A. Saint Remy, and L. Nick. 1990. Renal effects of cadmium body burden of the general populatoin. The Lancet 335:699–762.
Bullock, A.D., J.J. Becich, C.G. Klutke, and T.L. Ratliff. 1992. Experimental autoimmune cystitis: A potential murine model for ulcerative interstitial cystitis. J. Urol. 148:1951–1956.
Burg, M. b., and M.A. Knepper. 1986. Single ruble perfusion techniques. Kidney Int. 30:166–170.
Burns, C.P., and E. Rozengurt. 1984. Extracellular Na+ and initiation of DNA synthesis: Role of intracellular pH and K+. J. Cell Biol. 98:1082–1089.
Burton, B.T. and G.H. Hirschman. 1979. Demographic analysis: End-stage renal disease and its treatment in the United States. Clin. Nephrol. 11:47–51.
Bussemakers, M.J.G., W.B. Isaacs, B.S. Carter, W. Van de Ven, F.M.J. DeBruyne, and J.A. Schalken. 1991. Ecahedrin is a candidate trumor suppressor gene implicated in prostate cancer. J. Urol. 145:294A.
Buttyan, R., C.A. Olsson, J. Pintar, C. Chang, M. Bandyk, P. Ng., and I.S. Sawczuk. 1989. Induction of the TRPM-2 gene in cells undergoing programmed death. Molec. and Cell Biol. 9:3473–3481.
Byrne, C., J. Nedelman, and R.G. Luke. 1994. Race, socioeconomic status, and the development of end-stage renal disease. Amer. J. Kidney Dis. 23:16–22.
Cagnoli, L., S. Casanova, S. Pasquali, U. Donini, and P. Zucchelli. 1980. Relation between hydrocarbon exposure and the nephrotic syndrome. BMJ 280:1068–1069.
Cairns, P., A.J. Proctor, and M.A. Knowles. 1991. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 6:2305–2309.
Cantrell, B.B., D.P. DeKlerk, J.C. Eggleston, J.K. Boitnott, and P.C. Walsh. 1981. Pathological factors that influence prognosis in state A prostatic cancer: The influence of extent versus grade. J. Urol. 125:516–520.
Capella, C., L. Usellini, R. Buffa, B. Frigerio, and e. Solcia. 1981. The endocrine component of prostatic carcinomas, mixed adenocarcinoid tumours and non-tumour prostate: Histochemical and ultrastructural identification of the endocrine cells. Histopathology 5:175–192.
Carbin, B.E., P. Ekman, P. Eneroth, and B. Nilsson. 1989. Urine-TPA (tissue polypeptide antigen), flow cytometry and cytology as markers for furnor invasiveness in urinary bladder carcinoma. Urol. Res. 17:269–272.
Carlisle, E.J., S.M. Donnelly, S. Vasuvattakul, K.S. Kamel, S. Tobe, and M.L. Halperin.
OCR for page 227
Biologic Markers in Urinary Toxicology
Tsau, Y.K., J.T. Norman, and L.G. Fine. 1989. Epidermal growth factor (EGF) enhances renal regeneration and accelerates recovery, from ischemic acute renal failure [abstract]. Kidney Int. 35:420.
Tsukamoto, T., Y. Kumamoto, K. Yamazaki, T. Umehara, N. Miyao, K. Ohmura, and M. Iwazawa. 1988. Clinical study of tumor markers in prostatic carcinoma--an investigation on the simultaneous measurement of prostatic acid phosphatase (PAP), prostatic antigen (PA) and gamma-seminoprotein (gamma-Sm) [in Japanese] Hinyokika Kiyo (Acta Urol. Jpn.) 34:987–995.
Tucker, B.J. and Blantz. 1977. Factors determining superficial nephron filtration in the mature, growing rat. Am. J. Physiol. 232:F97.
Tune, B.M. 1986. The nephrotoxicity of cephalosporin antibiotics-Structure-activity relationships. Comments Toxicol. 1:145–170.
Tupper, J.T., F. Zorgniotti, and B. Mills. 1977. Potassium transport and content during G1 and S phase following serum stimulation of 3T3 cells. J. Cell Physiol. 91:429–440.
Turbat-Herrera, E.A., G.A. Herrera, I. Gore, R.L. Lott, W.E. Grizzle, and J.M. Bonnin. 1988. Neuroendocrine differentiation in prostatic carcinomas: A retrospective autopsy study. Arch. Pathol. Lab. Med. 112:1100–1106.
Tyson, C.K., and J.C. Mirsalis. 1985. Measurement of unscheduled DNA synthesis in rat kidney cells following in vivo treatment with genotoxic agents. Environ. Mutagen. 7:889–899.
Uchida, T., K. Shinohara, K. Kobayashi, N. Honda, T. Ao, T. Omata, K. Odajima, and K. Koshiba. 1986. Tumor markers in renal cell carcinoma [in Japanese] . Hinyokika Kiyo, (Acta Urol. Jpn.) 32:929–940.
Ullrich, K.J., and G. Rumrich. 1993. Renal transport mechanisms for xenobiotics: Chemicals and drugs. Clin. Invest. 71:843–848.
Ulrich, K.J., G. Rumrich, T. Wieland, and W. Dekant. 1989. Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of rat kidney. VI. Specificity: Amino acids, their N-methyl-, N-acetyl-, and N-benzoyl derivatives; glutathione-and cysteine conjugates, di-and oligopeptides. Pflfgers Arch. 415:342–350. (Chapter 3)
Umbas, R., J.A. Schalken, T.W. Aalders, B.S. Carter, H.F.M. Karthaus, H.E. Schaafsma, F.M.J. Debruyne, and W.B. Isaacs. 1992. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52:5104–5109.
Unger, P.D., C.W. Watson, Z. Liu, and J. Gil. 1993. Morphometric analysis of neoplastic renal aspirates and benign renal tissue. Anal. Quant. Cytol. Histol. 15:61–66.
USRDS (United States Renal Data System). 1991, United States Renal Data System, USRDS 1991 Annual Report, Bethesda, MD , The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, August 1991.
OCR for page 227
Biologic Markers in Urinary Toxicology
USRDS (United States Renal Data System). 1993. Annual Report.
Valles, A., G. Tucker, J. Thiery, and B. Boyer. 1990. Alternative patterns of mitogenesis and cell scattering induced by acidic FGF as a function of cell density in a rat bladder carcinoma cell line. Cell Regul. 1:975–988.
Vamvakas, S., A. Küchling, K. Berthold, and W. Dekant. 1989a. Cytotoxicity of cysteine S-conjugates: Structure-activity relationships. Chem.-Biol. Interact. 71:79–90.
Vamvakas, S., W. Dekant, and M.W. Anders. 1989b. Mutagenicity of benzyl S-haloalkyl and S–74 haloalkenyl Sulfides in the Ames test. Biochem. Pharmacol. 38:935–939.
Vamvakas, S., W. Dekant, and D. Henschler. 1989c. Assessment of unscheduled DNA synthesis in a cultured line of renal epithelial cells exposed to cysteine S-conjugates of haloalkanes and haloalkenes. Mutation Res. 222:329–335.
Vamvakas, S., M. Herkenhoff, W. Dekant, and D. Henschler. 1989d. Mutagenicity of tetrachloroethene in the Ames test--metabolic activation by conjugation with glutathione. J. Biochem. Toxicol. 4:21–27.
van Dalen, A., D.H. Helmhout, and R.D. van Caubergh. 1988. The contribution of prostatic acid phosphatase and prostatic specific antigen in the diagnosis of prostatic cancer. Int. J. Biol. Markers 3:123–126.
vanden Houte, K., R. Kiss, C. de Prez, A. Verhest, J.L. Pasteels, and R. Van Velthoven. 1991. Use of computerized cell image analysis to characterize cell nucleus populations from normal and neoplastic renal tissues. Eur. Urol. 19:155–164.
van der Hout, A.H., E. van den Berg, P. van der Vlies, T. Dijkhuizen, S. Storkel, J.W. Oosterhuis, B. de Jong, and C.H. Buys. 1993. Loss of heterozygosity at the short arm of chromosome 3 in renal-cell cancer correlates with the cytological tumour type. Int. J. Cancer 53:353–357.
van der Poel, H., M. Boon, L. Kok, E. van der Meulen, R. van Caubergh, et al. 1991. Morphometry, densitometry and pattern analysis of plastic-embedded histologic material from urothelial) cell carcinoma of the bladder. Anal. Quant. Cytol. Histol. 13:307–315.
van Dierendonck, J., J. Wijsman, R. Keijzer, C.H. van de Velde, and C. Cornelisse. 1991. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Am. J. Pathol. 138:1165–1172.
Vandoren, G., B. Mertens, W. Heyns, H. Van Baelen, W. Rombauts, and G. Verhoeven. 1983. Different forms of α2u-globulin in male and female rat urine. Eur. J. Biochem. 134:175–181.
van Leeuwen, E.H., A. Postma, J.W. Oosterhuis, A. Meiring, C.J. Cornelisse, J. Koudstaal, W.M. Molenaar. 1987. An analysis of histology and DNA-ploidy in primary wilms tumors and their metastases and a study of the morphological effects of therapy. Virchows Arch. A: Pathol. Anat. Histopathol. 410:487–494.
van Weerden, W.M., E.P. Moerings, A. van Kreuningen, F.H. de Jong, G.J. van
OCR for page 227
Biologic Markers in Urinary Toxicology
Steenbrugge, and F.H. Schroeder. 1993. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif. 26:67–75.
Vancura, P., L. Miller, J.W. Little, and R.A. Malt. 1970. Contribution of glomerular and tubular RNA synthesis to compensatory renal growth. Am. J. Physiol. 219:78–83.
Veloso, J.D., O.G. Solis, J.H. Barada, H.A. Fisher, and J.S. Ross. 1992. DNA ploidy of oncocytic-granular renal cell carcinomas and renal oncocytomas by image analysis. Arch. Pathol. Lab. Med. 116:154–158.
Verpooten, G.F., E.J. Nouwen, M.F. Hoylaerts, P.G. Hendrix, and M.E. De Broe. 1989. Segment-specific localization of intestinal-type alkaline phosphatase in human kidney. Kidney Int. 36:617–625.
Verstrepen, W., E.J. Nouwen, Y. Ziaosheng, and M. De Broe. 1991. Expression of EGF, TGF-alpha, and PDGF-A in the rat kidney during regeneration after acute aminoglycoside toxicity. JASN 2:447A.
Viau, C., A. Bernard, R. Lauwerys, J.P. Buchet, L. Quaeghebeur, M.E. Cornu, S.C. Phillips, A. Mutti, S. Lucertini, and 1. Franchini. 1987, A cross sectional survey of kidney function in oil refinery employees. Am. J. Ind. Med. 11:177–187.
Vinay, P., A. Gougoux, and G. Lemieux. 1981. Isolation of a pure suspension of rat proximal tubules. Am. J. Physiol. 241: F403-F411.
Visakorpi, T., O.P. Kallioniemi, I.Y. Paronen, J.J. Isola, A.I. Heikkinen, and T.A. Koivula. 1991. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: Implications for prognosis and response to endocrine therapy. Br. J. Cancer 64:578–582.
Voeller, H., G. Wilding, and E. Gelmann. 1991. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol. Endicrol 5:209–216.
Volm, M., and T. Efferth. 1990. Relationship of DNA ploidy to chemoresistance of tumors as measured by in vitro tests. Cytometry 11:406–410.
Volm, M., M. Kastel, J. Mattern, and T. Efferth. 1993. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas . Cancer 71:3981–3987.
Vonder Hude, W., A. Basler, R. Mateblowski, and G. Obe. 1989. Genotoxicity of epoxides II. In vitro investigations with the sister chromatid exchange (SCE) test and the unscheduled DNA synthesis (UDS) test. Mutagenesis 4:323.
Vuitch, M.F.; Mendelsohn, G. Relationship of ectopic ACTH production to tumor differentiation: a morphologic and immunohistochemical study of prostatic carcinoma with Cushing's syndrome.. Cancer 47:296–299; 1981.
Waber, P.G., J. Chen, and P.D. Nisen. 1993. Infrequency of ras, p53, WTI, or RB gene alterations in Wilms tumors. Cancer 72:3732–3738.
OCR for page 227
Biologic Markers in Urinary Toxicology
Wade, T.P., L.G. Comelia, E.R. Sargent, P. Anglard, A. Kasid, and W.M. Linehan. 1989. Southern blot analysis of transformed growth factor alpha and beta DNA in normal kidney and in renal cell carcinoma. Curr. Surg. 46:401–403.
Waldmann, T.A., W. Strober, and R.P. Mogielnicki. 1972. The renal handling of low molecular weight proteins. J. Clin. Invest. 51:2162.
Waldman, F.M., P.R. Carroll, R. Kerschmann, M.B. Cohen, F.G. Field, and B.H. Mayall. 1991. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res. 51:3807–3813.
Waldman, F.M., P.R. Carroll, M.B. Cohen, R. Kerschmann, K. Chew, and B.H. Mayall. 1993. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder. Mod. Pathol. 6:20–24.
Walker, R.J., and G.G. Duggin. 1988. Drug nephrotoxicity. Annu. Rev. Pharmacol. Toxicol. 28:331–345.
Walker, K.Z., P.J. Russell, E.A. Kingsley, J. Philips, and D. Raghavan. 1989. Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. J. Urol, 142:1578–1583.
Walker, C., L. Recio, K. Funaki, and J. Everitt. 1992. Cytogenetic and molecular correlates between rodent and human renal cell carcinoma [review] . Prog. Clin. Biol. Res. 376:289–302.
Wallace, A.C., and R.C. Nairn. 1972. Renal tubular antigens in kidney tumors. Cancer 29:977–981.
Wallin, A., R.G. Gerdes, R. Morgenstern, T.W. Jones, and K. Ormstad. 1988. Features of microsomal and cytosolic glutathione conjugation of hexachlorobutadiene in rat liver. Chem.-Biol. Interact. 68: 1–11.
Wallin, A., G. Zhang, T. Jones, S. Jaken, and J. Stevens. 1992. Mechanism of the nephrogenic repair response. Lab. Invest. 66:474–484.
Walzer, M. 1982. Delay of progression of renal failure. Pp. 23–30 in Prevention of Kidney Disease and Long-Term Survival, M.M. Avram, ed. New York: Plenum.
Wang, Z. 1991. Oncogene ras P 21 expression and DNA ploidy in human bladder tumor [in Chinese]. Zhonghua Zhongliu Zazhi 13:245–248.
Wang, T., and T. Kawaguchi. 1987. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. Ann. Clin. Lab. Sci. 16:461–466.
Wang, M.C., L.A. Valenzuela, G.P. Murphy, and T.M. Chu. 1979. Purification of a human prostate specific antigen. Invest. Urol. 17:159–63.
Watanabe, T., A. Hiratusuka, M. Isobe, and N. Ozawa. 1980. Metabolism of d-Limonene by hepatic microsoms to monmutagenic epoxides toward salmonella typhimurium. Biochem. Pharmacol. 29:1068.
Watanabe, M., Y. Kitamura, S. Komatsubara, and Y. Sakata. 1988. Role of
OCR for page 227
Biologic Markers in Urinary Toxicology
gamma-seminoprotein (gamma-SM) and prostatic acid phosphatase (PAP) as tumor markers of prostatic cancer [in Japanese]. Hinyokika Kiyo (Acta Urol. Jpn.) 34:2135–2141.
Waters, W.B., and J.P. Richie. 1979. Aggressive surgical approach to renal cell carcinoma. Review of 130 cases. J. Urol. 122:306–309.
Weaver, M.G., F.W. Abkul-Karim, J. Strigley, D.G. Bostwick, J.Y. Ro, and A.G. Ayala. 1992. Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study. Am. J. Surg. Pathol. 16:62–68.
Weaver, D.J., K. Michalski, and J. Miles. 1988. Cytogenetic analysis in renal cell carcinoma: Correlation with tumor aggressiveness. Cancer Res. 48:2887–2889.
Webb, D.R., G.M. Ridder, and C.L. Alden. 1989. Acute and subchronic nephrotoxicity of d-limonene in Fischer 344 rats. Food Chem. Toxicol. 27:639–649.
Weber, P., and J. Rohner. 1987. Importance of acid phosphatase in response criteria for prostate cancer. Urology 30:316–317.
Webster, K.D., and M.W. Anders. 1989. Bioactivation mechanism of L-thiomorpholine-3-carboxylic acid. Arch. Biochem. Biophys. 273:562–571.
Webster, G.D., J.C. Touchstone, and M. Suzuki. 1959. Adenocortical hyperplasia occurring with metastatic carcinoma of the prostate: Report of a case exhibiting increased urinary aldosterone and glucocorticoid excretion. J. Clin. Endocrinol. 19:967–979.
Weghorst, C.M., K.H. Dragnev, G.S. Buzard, K.L. Thorne, G.F. Vandeborne, K.A. Vincent, and J.M. Rice. 1994. Low incidence of point mutations detected in the p53 tumor suppressor gene from chemically induced rat renal mesenchymal tumors. Cancer Res. 54:215–219.
Weidner, U., S. Peter, T. Strohmeyer, R. Hussnatter, R. Ackermann, and H. Sies. 1990. Inverse relationship of epidermal growth factor receptor and HER-2/neu gene expression in human renal cell carcinoma. Cancer Res. 50:4504–4509.
Weinberg, J.M., J.A. Davis, M. Abarzua, T. Kiani, and R. Kunkel. 1990. Glycine-dependent protection of proximal tubules against lethal cell injury due to inhibitors of mitochondrial ATP production. Am. J. Physiol. 258:C1127–C1140.
Weiss, R. 1989. Predisposition and prejudice. Sci. News 135:40–42.
Weiss, L.M., M.J. Gaffey, M.J. Warhol, P. Mehta, S.M. Bonsib, E. Bruder, E. Santos, and L.J. Mederios. 1991. Immunocytochemical characterization of a monoclonal antibody directed against mitochondria reactive in paraffin-embedded sections . Mod. Pathol. 4:596–601.
Wells, D., B. Bennett, and W.J. Gardner. 1985. Uses and limitations of prostate-specific antigen in the laboratory, diagnosis of prostate cancer. South. Med. J. 81
Wenk, R.E., B.S. Bhagavan, R. Levy, D. Miller, and W. Weisburger. 1977. Ectopic
OCR for page 227
Biologic Markers in Urinary Toxicology
ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 40:773–778.
Werber, A., S.N. Emancipator, M.L. Lykocinski, and J.R. Sedor. 1987. The interleukin 1 gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis. J. Immunol. 138:3207–3212.
Wernert, N., M.B. Raes, P. Lassalle, M.P. Dehouck, B. Gosselin, B. Vandenbunder, and D. Stehelin. 1992. c-etsl proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am. J. Pathol. 140:119–127.
West, S.S. 1970. Biophysical Cytochemistry. Page 451 in Introduction to Quantitative Cytochemistry , Vol. II, G.L. Weid, and G.F. Bahr, eds. New York: Academic Press.
West, S.S., G.P. Hemstreet, R.E. Hurst, et al. 1987. Detection of DNA aneuploidy by quantitative fluorescence image analysis: Potential in screening for occupational bladder cancer. Pp. 327–341 in Biological Monitoring of Exposure to Chemicals, Vol. I. Organic Chemicals, H.K. Dillon, and M. Ho, eds. New York: Wiley.
Wheeless, L.L., J. Coon, C. Cox, A. Deitch, R.W. DeVere White, et al. 1991. Precision of DNA flow cytometry in inter-institutional analyses. Cytometry 12:405–412.
Wheeless, L.L., R.A. Badalament, R.W. DeVere White, Y. Fradet, and B. Tribukait. 1993. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Cytometry 14:478–481.
Wibel, L., and A. Karlsson. 1976. Urinary excretion of β2-microglobulin after the induction of a diuresis. A study in healthy subjects. Nephron 17:343–352.
Wiggins, R.C., A. Glatfelter, and J. Brukman. Procoagulant activity in glomeruli and urine of rabbits with nephrotoxic nephritis. Lab. Invest. 53:156–165.
Wille, J.J., J. Park, and A. Elgavish. 1992. Effects of growth factors, hormones, bacterial lipopolysaccharides, and lipotechoic acids on the clonal growth of normal ureteral epithelial cells in serum-free culture. J. Cell Physiol. 150:52–58.
Willems, M., H. Musilova, and R.A. Malt. 1969. Giang nucleoplasmic RNA in ''switch on'' of compensatory renal growth, Proc. Natl. Acad. Sci. U.S.A. 62:1189–1194.
Wilson, C.B. 1982. Drug-and toxin-induced nephrotodes: Anti-kidney antibody and immune complex mediation. Pp. 383–392 in Nephrotoxic Mechanisms of Drugs and Environmental Toxins, G.A. Porter, ed. New York: Plenum.
Wilson, P.D., R.J. Anderson, R.D. Breckon, W. Nathrath, and R.W. Schrier. 1987. Retention of differentiated characteristics by cultures of defined rabbit kidney epithelia. J. Cell. Physiol. 130:245–254.
Wise, H.M., A.L. Fohl, A. Gazzaniga, J.H. Harrison. 1965. Hyperadrenocorticism associated with "reactivated" prostatic carcinoma. Surgery 57:655–664.
Wolf, G., and E.G. Neilson. 1990. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am. J. Physiol. 259:F768–F777.
OCR for page 227
Biologic Markers in Urinary Toxicology
Wolf, G., and E.G. Neilson. 1991. Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia. Kidney Int. 39:401–420.
Wolff, G., P.D. Killen, and E.G. Neilson. 1990. Cyclosporin A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. J. Am. Soc. Nephrol. 1:918–922.
Wolfgang, G.H.I., A.J. Gandolfi, J.L. Stevens, and K. Brendel. 1989, N-Acetyl S-(1,2-dichlorovinyl)-L-cysteine produces a similar toxicity to S-(1,2-dichlorovinyl)-L-cysteine in rabbit renal slices: Differential transport and metabolism. Toxicol. Appl. Pharmacol. 101:205–219.
Wood, D.P., D.D. Wartinger, V. Reuter, C. Cordon-Cardo, W.R. Fair, and R.S. Chaganti. 1991. DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. J. Urol. 146:1398–1401.
Wood, D.P., W.R. Fair, and R.S. Chaganti. 1992. Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer. J. Urol. 147:274–277.
Woolf, C.M. 1960. An investigation of the familial aspects of carcinoma of the prostate. Cancer 13:739–744.
Woolhandler, S., R.J. Pels, D.H. Bor, D.U. Himmelstein, and R.S. Lawrence. 1989. Dipstick urinalysis of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA 262:1214–1219.
Wright, C., K. Mellon, P. Johnston, D.P. Lane, A.L. Harris, C.H. Horne, and D.E. Neal. 1991. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer 63:967–970.
Wu, S.-Q., B.E. Storer, E.A. Bookland, A.J. Klingelhutz, K.W. Gilchrist, L.F. Meisner, R. Oyasu, and C.A. Reznikoff. 1991. Nonrandom chromosome losses in stepwise neoplastic transformation in vitro of human uroepithelial cells. Cancer Res. 51:3323–3326.
Wuthrich, R., M.A. Yui, G. Mazoujian, N. Nabavi, L.H. Glimcher, and V.E. Kelley. 1989. Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am. J. Path. 134:45–51.
Wuthrich, R.P., A.M. Jevnikar, F. Takei, L.H. Glimcher, and V.E. Kelley. 1990. Intercellular adhesion molecule-1 (ICAM-l) expression is preregulated in autoimmune murine lupus nephritis. Am. J. Path. 136:441–450.
Yagoda, A., and N.H. Bander. 1989. Failure of cytotoxic chemotherapy, 1983–1988, and the emerging role of monoclonal antibodies for renal cancer [review]. Urol. Int. 44:338–345.
Yamada, T., I. Fukui, T. Kobayashi, H. Sekine, M. Yokogawa, and H. Oshima. 1991. The relationship of ABH(O) blood group antigen expression in intraepithelial
OCR for page 227
Biologic Markers in Urinary Toxicology
dysplastic lesions to clinicopathologic properties of associated transitional cell carcinoma of the bladder. Cancer 67:1661–1666.
Yamakawa, K., R. Morita, E. Takahashi, T. Hori, J. Ishikawa, and Y. Nakamura. 1991. A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res. 51:4707–4711.
Yamamoto et al. 1994.
Yamazaki, K., Y. Kumamoto, T. Tsukamoto, K. Ohmura, N. Miyao, and T. Yoshioka. 1988. The clinical investigation of tumor markers for renal cell carcinoma--a comparison among TPA, ferritin and immunosuppressive substance [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 79:28–34.
Yamazaki, K., Y. Kumamoto, T. Tsukamoto, K. Ohmura, N. Miyao, M. Yoshioka, A. Iwasawa. 1991. Immunosuppressive acidic protein (IAP) and immunosuppressive substance (ISS) in patients with renal cell carcinoma (in Japanese). Hinyokika Kiyo (Acta Urol. Jpn.) 37:467–474.
Yao, M., T. Shuin, H. Misaki, and Y. Kubota. 1988. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 48:6753–6757.
Yaqoob, M., and G.M. Bell. 1994. Occupational factors and renal disease. Renal Failure 16:425–434.
Yaqoob, M., G.M. Bell, D. Perdy, and R. Finn. 1992a. Primary glomerulonephritis and hydrocarbon exposure: A case control study and literature review. Q. J. Med. 301:409–418.
Yaqoob, M., A.W. Patrick, P. McClelland, A. McGregor, H. Mason, M.C. White, and G.M. Bell. 1992b. High hydrocarbon exposure in diabetic nephropathy. Nephrol. Dial. Transplant. 8:1157–1158.
Yaquoob, M., A. Stevenson, H. Mason, and G.M. Bell. 1993. Hydrocarbon exposure and tubular damage: Additional factors in the progression of renal failure in primary glomerulonephritis. Q. J. Med. 86:661–667.
Yogi, S., T. Ikeuchi, H. Yoshikawa, T. Hamashima, H. Sasaki, F. Morikawa, Y. Onodera, K. Matsumoto, and Y. Kai. 1991. Clinical evaluation of the bladder tumor marker "Tu-MARK-BTA" [in Japanese]. Hinyokika Kiyo (Acta Urol. Jpn.) 37:335–339.
Yorimitsu, K., O. Shinmi, M. Nishiyama, K. Moroi, Y. Sugita, T. Saito, Y. Inagaki, T. Masaki, and S. Kimura. 1992. Effect of phosphoramidon on big endothelin-2 conversion into endothelin-2 in human renal adenocarcinoma (ACHN) cells. Analysis of endothelin-2 biosynthetic pathway. FEBS Lett. 314:395–398.
Yoshida, S.O., A. Imam, C.A. Olson, and C.R. Taylor. 1986. Proximal renal tubular surface membrane antigens identified in primary and metastatic renal cell carcinomas. Arch. Pathol. Lab. Med. 110:825–832.
Yoshida, M.A., T. lkeuchi, Y. Tachibana, K. Takagi, M. Moriyama, and A. Tonomura.
OCR for page 227
Biologic Markers in Urinary Toxicology
1988. Rearrangements of chromosome 3 in nonfamilial renal cell carcinomas from Japanese patients. Jpn. J. Cancer Res. 79:600–607.
Yoshiki, T., K. Okada, K. Oishi, and O. Yoshida. 1987. Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein [in Japanese] . Hinyokika Kiyo, (Acta Urol. Jpn.) 33:2044–2049.
Yoshimura, A., K. Gordon, C.E. Alpers, J. Floege, P. Pritzl, R. Ross, W.G. Couser, D.F. Bowen-Pope, and R.J. Johnson. 1991. Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney Int. 40: 470–476.
Yoshioka, K., T. Takemura, M. Tohda, N. Akano, H. Miyamoto, A. Ooshima, and S. Maki. 1989. Glomerular localization of type III collagen inhuman kidney disease. Kidney Int. 35:1203–1211.
Young, D.A., G.R. Prout, and C.-W. Lin. 1985. Production and characterization of mouse monoclonal antibodies to human bladder-tumor associated antigens. Cancer Res. 45:4439–4446.
Young, E.W., E.A. Mauger, K-H. Jiang, F.K. Port, and R.A. Wolfe. 1994. Socioeconomic status and end-stage renal disease in the United States. Kidney Int. 45:907–911.
Yu, D.S., J. Wang, S.Y. Chang, and C.P. Ma. 1991. Flow cytometric analysis of DNA ploidy, cell cycle and cytomorphometry in sarcomatoid renal cell carcinoma. Eur. Urol. 20:227–231.
Yu, D.S., C.M. Hsu, W.H. Lee, S.Y. Chang, and C.P. Ma. 1993. Flow cytometric DNA and cytomorphometric analysis in renal cell carcinoma: Its correlation with histopathology and prognosis. J. Surg. Res. 55:480–485.
Yun, S.K., D.J. Laub, D.L. Weese, P.M. Lad, G.E. Leach, and P.E. Zimmern. 1992. Stimulated release of urine histamine in interstitial cystitis. J. Urol. 148:1145–1148.
Yura, Y., O. Hayashi, M. Kelly, and R. Oyasu. 1989. Identification of epidermal growth factor as a component of the rat urinary bladder tumor-enhancing urinary fractions. Cancer Res. 49:1548–1553.
Zager, R.A. 1988. Gentamicin nephrotoxocity in the setting of renal hypoperfusion. Am. J. Physiol. 254:F574–F581.
Zager, R.A., and H.M. Sharma. 1983. Gentamicin increases renal susceptibility to an acute ischemic insult. J. Lab. Clin. Med. 101:670.
Zager, R.A., and M.A. Venkatachalam. 1983. Potentiation of ischemic renal injury by amino acid infusion. Kidney Int. 24:620–625.
Zalups, R.K., and L.H. Lash. 1990. Effects of uninephrectomy and mercuric chloride on renal glutathione homeostasis. J. Pharmacol. Exp. Ther. 254:962–970.
Zalups, R.K., and J.C. Veltman. 1988. Renal glutathione homeostasis in compensatory renal growth. Life Sci. 42:2171–2176.
Zalups, R.K., K.L. Knutson, and R.G. Schnellmann. 1993. In vitro analysis of the
OCR for page 227
Biologic Markers in Urinary Toxicology
accumulation and toxicity of inorganic mercury in segments of the proximal tubule isolated from the rabbit kidney. Toxicol. Appl. Pharmacol. 119:1–7.
Zenser, T.V., and B.B. Davis. 1984. Enzymes systems involved in the formation of reactive metabolites in the renal medulla: Cooxidation via prostaglandin H synthase. Fund. Appl. Toxicol. 4:922–929.
Zhang, G., and J.L. Stevens. 1989. Transport and activation of S-(1,2-dichlorovinyl)-L-cysteine and N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine in rat kidney proximal tubules. Toxicol. Appl. Pharmacol. 100:51-61.
Zimmerman, S.W., K. Groehler, and G.J. Beirne, 1975. Hydrocarbon exposure and chronic glomerulonephritis. Lancet 2:199–202.
Zoja, C., N. Perico and G. Remuzzi. 1989. Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. Toxicol. Lett. 46:65–75.
Zumkeller, W., J. Schwander, C.D. Mitchell, D.J. Morrell, P.N. Schofield, and M.A. Preece. 1993. Insulin-like growth factor (IGF)-I,-II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. Eur. J. Cancer 29A: 1973–1977.
OCR for page 227


text:
S&P Falls To 12 Year Low On Third Citi Rescue
Stocks fell to a 12-year low Friday as a move by the U.S. government to take a large stake in common shares of embattled Citigroup fanned nervous whispers that other banks could go the same way.
Although the U.S. Treasury is not infusing Citigroup with any new capital, it will convert up to $25 billion in preferred shares to common stock in its third attempt to prop up the bank in the past five months
The deal is contingent on private investors also agreeing to a similar swap. Existing common shareholders would see their ownership stake shrink to as little as 26%.
It probably comes as no surprise that shares of Citi tumbled while the KBW Bank index of larger banks dropped substantially, as well.
Strategy Session with the Fast Money Traders
After news like that, no one wants to go long into the weekend, explains Pete Najarian. That's what triggered the late day sell-off.
Closes like this on Friday make it easy to push slightly past support, says Jeff Macke. Don't make too much of that but make no mistake we are right at support in the S&P.
It seems to me that there's a ton of pessimism in the market, adds Joe Terranova. And that could be enough to get long. It's making celebrated contrarian investor Doug Kass bullish.
From the perspective of preferred shareholders the news on Citigroup is a home run, explains Karen Finerman. Citi preferred shares traded a third higher because the market had discounted something much worse. My trade going forward is longBank of Americapreferred and short the Bank of America common against it.
If you have a Wharton background go ahead and buy preferred shares, counters Terranova. Otherwise stay away from Citigroup. Instead I'd look at Morgan Stanley and Goldman Sachs.
As far as I'm concerned Citigroup did the deal with the government to avoid a downgrade from credit ratings agency, bristles Jeff Macke. They sold common shareholders up the river to hold onto their credit rating.
I totally disagree, counters Karen Finerman. Equity shareholders are risk takers. They shouldn't be saved.
General Electric plans to cut its quarterly dividend by 68 percent to 10 cents a share, starting in the second half of 2009, a move that it said would provide it with more "flexibility" in the face of a recession.
The U.S. conglomerate said that it had no plans to raise additional equity, and that reducing its dividend from 31 cents a share would save it about $9 billion a year.
I think it's a smart move, muses Karen Finerman.
Despite the rough tape, technology stocks appear to be holding most of their ground with the Technology SPDR ETF only down 2%. Both Dell and IBM finished the day in positive territory with investors liking Michael Dell's cost cutting plans and IBM's guidance.
I'm long Dell, explains Joe Terranova. I think Dell could get to $11 very easily. It's massively shorted and at some point short sellers will have to cover that trade.
I don't like Dell, counters Pete Najarian. I don't see any growth coming. Instead I'd look at IBM. That company is doing well on their service revenues.
Investors are wondering if gold's $1000 move was, in fact, the top. The precious metal plunged 6% this week despite a strong environment for safe haven plays.
$920 - $930 should be a point of support, says Joe Terranova.
Although it settled lower on Friday, oil jumped big for the week, soaring a whopping 12%. Meanwhile coal producers such as Massey and Arch Coal traded higher.
In the energy complex nat gas made a 6-year low and then turned around, says Joe Terranova. It looks like the space is coming together and I think it's a buy. Personally, I'm long ConocoPhillips $35 calls.
In commodities I like the ag names, adds Pete Najarian. There's a Credit Suisse conference coming out the week after next and it could create a catalyst for ag stocks.
Got something to to say? Send us an e-mail at email@example.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to firstname.lastname@example.com.
Trader disclosure: On Feb. 27th, 2009, the following stocks and commodities mentioned or intended to be mentioned on CNBC's Fast Money were owned by the Fast Money traders; Najarian Owns (DNA) Calls; Najarian Owns (DOW) Call Spread; Najarian Owns (FCX) Call Spread; Najarian Owns (GDX) & (GDX) Short Calls; Najarian Owns (GS) Call Spread; Najarian Owns (MSFT); Najarian Owns (MS) & (MS) Short Calls; Najarian Owns (MOS) Stock; Najarian Owns (V) & (V) Calls; Terranova Owns (OTS), (DIS), (FXC), (XBI), (BRCM), (WYNN), (INTC), (DELL), (JOYG); Terranova Owns (AMGN) & (AMGN) Puts; Terranova Owns (IBM) Call Spread; Macke Owns (MS), (GS), (SDS), (TM); Finerman's Firm Owns (MSFT), (RIG); Finerman's Firm Owns (DNA) & (DNA) Calls; Finerman's Firm Owns (BAC) Preferred; Finerman's Firm Owns (WFC) Preferred; Finerman's Firm Is Short (IYR), (IJR), (IWM), (MDY), (SPY), (USO)
CNBC.com with wires

subset: commoncrawl


text:
engine - 1:46 pm on Mar 30, 2005 (gmt 0)
I'm not solely speaking of news releases, but of "informed comment." Syndication of free feeds will continue, but the jucier stories and informed comment will come via subscription. I support the concept.
I'm inclined to agree with you however, a lot of the material that is generated actually originates from some of the type of organisations suggested. The "free sources" are often fed from that news.


text:
Definition of 'Bookie'
Someone who facilitates gambling, commonly on sporting events, by setting odds, accepting and placing bets, and paying out winnings on behalf of other people. "Bookie" is a slang term for "bookmaker." Bookies do not usually make their money by placing bets themselves, but by charging a transaction fee on their customers' bets known as a "vigorish," or "the vig." Bookies may also lend money to bettors.
Investopedia explains 'Bookie'
The types of gambling enabled by bookies are not always legal. Bookmaking and placing bets through a bookmaker can also be illegal. The legality of different types of gambling is determined by state governments. Some people have referred to their broker as their bookie due to large commissions and the broker's insistence on trading with regularity.
Related Definitions
Articles Of Interest
Are You Investing Or Gambling?
We look at ways in which gambling creeps into trading, and what may drive an individual to trade - or gamble - in the first place. -
Winning The Jackpot: Dream Or Financial Nightmare?
Don't assume all prizes are free. Many come with enough costs to render them worthless. -
Going All-In: Comparing Investing And Gambling
People often compare stocks to gambling, but how close are they really? -
The Downward Spiral Of Trading Addiction
Trading in the financial markets is stimulating, exciting and engrossing. But one can become addicted, just like with actual casino gambling or illegal drugs. Like any severe addiction, this ... -
Follow The Herd In Trading The Capital Market
If you have ever heard "the trend is your friend" and believed it, you may be a fan of herd instinct mentality. This is an environment where, just like with fashion, masses of people follow a ... -
The Good And Bad Of National Lotteries
Here's a look at some of the positives and negatives of national lotteries. -
Investing Vs. Gambling: Where Is Your Money Safer?
Many people who have never invested before see it as just another form of gambling. Find out the truth. -
Making Money In Las Vegas
It's never been a worse time to break into the ranks of Vegas dealers and pit bosses. -
States That Spend The Most On Lottery Tickets
Here are the areas in the U.S. that spend plenty of money on lottery tickets. -
In Praise Of Lotteries
Lotteries are horrible investment alternatives, but they ought to be better respected as entertainment options.


text:
America's #1 Rated Catalog/Internet Merchant
Based on Customer Satisfaction†
Look here for an easy way to
navigate to your previously
viewed products.
Serving Size 1 Capsule
Amount Per Serving | % Daily Value | |
SoyLife® Soy Germ Complex (2% soy isoflavones) | 750 mg | * |
*Daily Value not established.
Other ingredients: Gelatin, may contain one or more of the following: microcrystalline cellulose (plant fiber), magnesium stearate, silica.
Suggested Use: As a dietary supplement, take one capsule three to four times per day with water.
SoyLife® is a registered trademark of Frutarom, Inc.
Earning your trust is our first
and only priority.


text:
Event | Date & Location | |
Anjelah Johnson | Friday, April 18, 2014 at 7:30 PM Maui Arts & Cultural Center | View Tickets |
Anjelah Johnson | Saturday, April 19, 2014 at 7:00 PM Neal S. Blaisdell Center - Concert Hall | View Tickets |
Anjelah Johnson | Saturday, April 19, 2014 at 9:30 PM Neal S. Blaisdell Center - Concert Hall | View Tickets |
Anjelah Johnson | Saturday, May 3, 2014 at 7:00 PM Granada Theatre - Santa Barbara | View Tickets |
Anjelah Johnson | Friday, September 12, 2014 at 7:00 PM Newmark Theatre | View Tickets |
Anjelah Johnson | Friday, September 12, 2014 at 10:00 PM Newmark Theatre | View Tickets |
Anjelah Johnson | Saturday, October 18, 2014 at 8:00 PM Baton Rouge River Center Theatre | View Tickets |
Anjelah Johnson | Sunday, October 26, 2014 at 8:00 PM Hard Rock Live - Orlando | View Tickets |
Anjelah Johnson Comedy Tickets |
If you are looking for an entertaining comedy show, Anjelah Johnson tickets are the way to go! This former Oakland Raiders cheerleader continues to tour the U.S., selling out her comedy shows. Born in San Jose California, Anjelah grew up with a dream in acting. She moved to Los Angeles to pursue that dream after being on the Oakland Raiders cheerleading squad and performing in Super Bowl XXXVII. Be sure to buy tickets to see Anjelah Johnson, comedy and cheerleader extraordinaire! Anjelah is perhaps best known for her character on MADtv, Bon Qui Qui the rude fast food employee which gained notoriety of the masses on youtube. This young star already has a notable resume; on top of her television and standup acts, she has been featured in films including Alvin and the Chipmunks: The Squeakquel, Our Family Wedding, and Marmaduke. A California native, Anjelah started her entertainment career in Los Angeles, and also became a cheerleader for the Oakland Raiders, where she was named Rookie of the Year and cheered in Super Bowl XXXVII. You can watch this taleneted young star do her thing live with tickets for an Anjelah Johnson comedy show, available right here. One of Anjelah's first viral videos Nail Salon" landed some of her first stand up gigs. In 2007, she decided to join the cast of MADtv's 13th season, and her character "Bon Qui Qui" attracted over 55 million people and her skits went viral online. She also recorded some songs and music videos as the character, and decided to sign with Atlantic Records to release a full album. Anjelah also appeared in a number of ads and commercials, and guest starred in various television shows, such as The Shield and Ugly Betty. In 2009, she released "That's How We Do It" as her first one hour special on Comedy Central. Her second special, The Homecoming Show, aired in 2013 on NUVOtv. Aside from her comedy stand ups and television shows, Anjelah has also appeared and starred in a number of movies, including Our Family Wedding and Alvin and the Chipmunks: The Squeakquel. Outside of filming, she is on the road performing her stand up at various venues throughout the U.S. |


text:
Air Jordan 1 Retro High OG "Bred"
October 14th, 2013 by Brendan Dunne | 38 comments
Last time the public had a crack at the Air Jordan 1 in this black/red/white combination the pair was a pretty difficult one to acquire. That was the outlet-only Air Jordan 1 "Banned", a sneaker that still stands as one of the triumphs of Jordan Brand's long history of retros. The sneakers will be back again this year with a slightly different build, albeit one that will maintain the "Nike Air" treatment. Get a full look at the Air Jordan 1 Retro High OG "Bred" with us after the break and remember they'll be in stores come December 28th, 2013.
Air Jordan 1 Retro Hi OG
Color: Black/Varsity Red-White
Style Code: 555088-023
Release Date: 12/28/13
Price: $140
These have came out multiple times I remember people used to b like I don't wear 1s they look too much like dunks but now they so hyped up its hell gettn a pair but I'll still cop don't want nothing else releasing in December
everybody at my school is already talking about these -_- its gonna be a long night trying to cop these in the ATL
These shits not even ogs what ogs was the old shcool ones these shit look whack as fuck so u put red an black with nike on air jordan ones an call them ogs these shit look so bad it's not even funny my feet gunna hurt In them
Uh ohhhh. What is this? Why its another retro Jordan release.Let's see all the people that blow this thread up. We'll see this shoe again in 2015 for $170. But I like that people are so interested in these, honestly. Hopefully afew New Balance and asics collabs drop around the same time so these J's are a major distraction lol.
n particular dese right here is a mus have for anyone w feet dat wears j's.
nothing is gonna stop me from gettin these. got my KOs but i need the real OG now. lovin it.
I already got 4 pair and trust me they are very nice. They're made of a real soft high quality leather or leather type material. Everybody will be more than happy with the quality of this shoe. Now you know what to do with that cash your gonna get for Christmas.
Ive waited too damn long. The 28th needs to hurry up. Last Jordan's Im ever fucking with
what about them taxi's and gamma 11 too...those sum hot kicks for the holiday too lol
@LxrdLeon Not for MEEEEEE!, but yeah ya'll lil young nigga's fucked it up for us wit the BRED 11's last Christmas at Arborplace bein to turnt up.
@Old Head 1 @donadamsky not authorized or inspected by nike. not real and not fakes!!!
@Memphislee69 Wouldn't trust any of that early release stuff. I can wait. Early release stores have a rep for selling b-grades. Even pre-order sites. You might find defects that are not consistent with pairs got from nike.com or other major retailers. If yours look good that's fine, but I'll never trust those sites.
@MrNolimit23 @LxrdLeon omg arbor place got HOH now this shit in atlanta getting crazier everyyear.
@Memphislee69 Yea i checked u out...they do look pretty good...they look like the same material as the royals
The shoes have no issues and if you want see them in outdoor natural light , go to channel Memphislee69 on You Tube. Already threw a review on there. Peace out.


text:
The Role of A Public Venture Capital Program in State Economic Development: The Case of Kansas Venture Capital, Inc
State-assisted venture capital programs are a popular strategy to stimulate entrepreneurship and small business development. This study estimated the number of job-years created from 1988 to 2000 by the publicly- assisted program Kansas Venture Capital, Inc. (KVCI). The impact of KVCI in job-years generated was measured net of hypothetical job growth under three alternative scenarios: portfolio firms failed without KVCI fundings, firms followed their national industry employment patterns without KVCI funding, or firms followed the employment change patterns of a comparison set of Kansas businesses. Duration model estimation results indicated that KVCI portfolio firms had significantly higher survival rates than comparison Kansas firms. The number of jobyears created and saved credited to KVCI investments varied from 391 to 13,576 and the cost per job year created and saved ranged from $296 to $10,281 depending on assumptions of firm employment change in the absence of KVCI investments. The findings indicate that impact assessment results are highly sensitive to underlying assumptions.Download Info
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.Bibliographic Info
Article provided by Mid-Continent Regional Science Association in its journal Journal of Regional Analysis and Policy.
Volume (Year): 34 (2004)
Issue (Month): 2 ()
Contact details of provider:
Web page: http://jrap-journal.org/index.htm
More information through EDIRC
Related research
Keywords: Financial Economics;References
References listed on IDEASPlease report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- John R. Baldwin & Paul K. Gorecki, 1991. "Firm Entry and Exit in the Canadian Manufacturing Sector, 1970-1982," Canadian Journal of Economics, Canadian Economics Association, vol. 24(2), pages 300-323, May.
This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.Statistics
Access and download statisticsCorrections
When requesting a correction, please mention this item's handle: RePEc:ags:jrapmc:132296. See general information about how to correct material in RePEc.For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (AgEcon Search).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.


text:
Table Of Contents
Release Notes for Cisco UCS Central, Release 1.1
New Software Features in Release 1.1
Known Limitations and Behaviors
Release Notes for Cisco UCS Central, Release 1.1
First Published: July 15, 2013Updated: December 12, 2013OL-29853-01This document describes system requirements, new features, resolved caveats, known caveats, and open caveats with workarounds for Cisco UCS Central software Release 1.1(1a) and 1.1(1b). This document also includes information that became available after the technical documentation was published.
Use this release notes as a supplement with the other documents listed in documentation roadmap http://www.cisco.com/go/unifiedcomputing/b-series-doc .
Make sure to review other available documentation on Cisco.com to obtain current information on Cisco UCS Central.
This document includes the following sections:
•New Software Features in Release 1.1
•Known Limitations and Behaviors
Revision History
Table 1 shows the revision history:
Cisco UCS Central, Release 1.1 allows you to take charge of the data center environment by delivering easy to use, integrated solution for managing multiple Cisco UCS Domains from a single management point with high availability. With Cisco UCS Central 1.1, you can efficiently manage server, storage and network policies and generate network traffic reports for your entire UCS environment in one or more data centers.
System Requirements
To access the browser based Cisco UCS Central GUI, your computer must meet or exceed the following minimum system requirements:
–Internet Explorer 9 and above
–Firefox 15 and above
–Chrome 22 and above
•Linux RHEL
–Firefox 15 and above
–Chrome 22 and above
–Firefox 15 and above
–Chrome 22 and above
–Safari 6 and above
Adobe Flash Player 11.7 and above.
For the Chrome browser, remove the bundled flash player and install the flash player from Adobe.
The released OVA or ISO is supported with ESXi4.1, ESXi5.0, and ESXi5.1GA.
The released ISO is supported with Microsoft Hyper-V Server 2008 R2 SP1 and Microsoft Hyper-V Server 2012.
Note If you are using Cisco UCS Release 1.1(1a), you must be running Cisco UCS Release 2.1(2a) or higher.
New Software Features in Release 1.1
Release 1.1(1a) supports the following:
•Global Service Profile and Templates
•Global Policies
•Server Policies
- Adapter- BIOS- Boot- IPMI Access Profiles- iSCSI Authentication- Host Firmware Packages- Local Disk Configuration- Power Control- Maintenance- Scrub- Serial over LAN- Server Pool- Server Pool Qualification- Stats Threshold- vNIC/vHBA Placement•Network Policies
- VLAN- vNIC- vNIC Template- Default vNIC Behaviour- QoS- Network Control- Dynamic vNIC Connection- LAN Connectivity- Threshold•Storage Policies
- VSAN- vHBA- vHBA Template- Default vHBA Behaviour- SAN Connectivity- Threshold•Policy Globalization and Localization
•Global VLAN and VSAN Support
•VLAN Aliasing
•Org Aware Policies
•Domain-specific ID pools
•Enhanced Inventory
•Network Statistics Collection and Aggregation
•Reporting on Collected Statistics for Networks
•Centralized XML API
•High Availability
•SNMP support
•64-Bit Support
•Service Profile Renaming
Release 1.1(1b) supports the following:
•LDAP Group maps
•Nested LDAP groups
Upgrading to 1.1(1b)
•To deploy a fresh installation of Cisco UCS Central, release 1.1(1b), you can use either the OVA file or ISO image. See Cisco UCS Central Install and Upgrade Guides for more information.
•If you want to upgrade from 1.1(1a) to 1.1(1b) use the ISO image.
•Upgrading from 1.0(1a) to 1.1(1b) is not supported.
Resolved Caveats
Resolved Caveats in Release 1.1(1b)
The following caveats are resolved in Release 1.1(1b):
Resolved Caveats in Release 1.1(1a)
The following caveats are resolved in Release 1.1(1a):
Open Caveats
Open Caveats in Release 1.1(1b)
The following caveats are found in Release 1.1(1b):
Open Caveats in Release 1.1(1a)
The following caveats are found in Release 1.1(1a):
Known Limitations and Behaviors
The following known limitations and behaviors are not otherwise documented:
Table 6 Known Limitations in Release 1.1
Defect ID Symptom Workaround CSCug39587
Running VMware vMotion, suspending a VM, or restoring a suspended VM on a Cisco UCS Central VM that is currently the primary node in a cluster results in process crashes on the node.
Before triggering a vMotion or suspend operation on the primary Cisco UCS Central VM, use the local-mgmt cluster lead b command in the Cisco UCS Central CLI to do an administrative failover, which changes the primary node to the secondary node.
CSCuh01992 The Estimate Impact option does not display that a reboot is required under some situations. For example:
•When you add or remove vNICs or vHBAs from an associated global service profile where the MAC or WWxN IDs are derived from ID pools.
•When you change policies in a global service profile to a policy that was created in Cisco UCS Central, and does not yet exist in Cisco UCS Manager.
•When a new host firmware pack with a different firmware version is selected in the global service profiles properties page.
•For vNICs/vHBAs in pools, add and remove vNICS and vHBAs during a maintenance window.
Estimate impact analysis works correctly for vNICs/vHBAs where the IDs are set manually.•For policies, create an unassociated local service profile in Cisco UCS Manager. Reference the new policy in the service profile.
Estimate impact analysis will now work correctly.•For host firmware packages, create a host firmware package in Cisco UCS Central under the same domain group as the global service profile. Create an unassociated service profile in Cisco UCS Manager and reference the new host firmware package in the service profile.
Estimate impact analysis will now work correctly. CSCud26491
A critical disk read speed fault is shown in an UCS Central deployed on a Hyper-V host.
None. In testing, it was found that the disk read speed measured on Hyper-V guests showed a lower speed in comparison to guests running on ESX on the same datastore. Typically, this didn't result in a functional impact.
Microsoft Hyper-V Server 2008 and 2012 experience time-drift issues.
Perform the following:
1. Disable the Time Synchronization option on the Central VM Guest OS using Hyper-V Manager.
2. Acquire a Redhat version 5.8 compatible Rescue CD and perfom the boot process. For more information, see http://www.redhat.com/advice/tips/rescue_mode.html
3. After booting the RedHat Rescue CD, mount the /boot filesystem to a temporary mount location, for example, /tmp/boot.
4. Open the grub.conf file, locate the kernel line, and add the following:
notsc divider=10It should look like:
************************UCSCentral#cat /boot/grub/grub.conf******************# grub.conf generated by anaconda## Note that you do not have to rerun grub after making changes to this file # NOTICE: You have a /boot partition. This means that# all kernel and initrd paths are relative to /boot/, eg.# root (hd0,0)# kernel /vmlinuz-version ro root=/dev/VolGroup00/LogVol00# initrd /initrd-version.img#boot=/dev/hdadefault=0timeout=0title Cisco UCS Centralroot (hd0,0)kernel /vmlinuz-2.6.18-308.11.1.el5 roroot=/dev/VolGroup00/LogVol00 notsc divider=10initrd /initrd-2.6.18-308.11.1.el5.img5. Reboot the system, and verify the change works successfully by monitoring for one hour.
When performing maintenance operations such as admin failover or pmon restart on a UCS Central VM running on VMware ESX, the file system goes into read-only state. For more information, see http://kb.vmware.com/selfservice/microsites/search.do?cmd=displayKC&externalId=51306.
There is no known workaround.
Documentation and Support
You can obtain documentation, submit a service request or find additional information from What's New in Cisco Product Documentation at: http://www.cisco.com/en/US/docs/general/whatsnew/whatsnew.html.
Subscribe to What's New in Cisco Product Documentation, which lists all new and revised Cisco technical documentation, as an RSS feed and deliver content directly to your desktop using a reader application. The RSS feeds are a free service.
For more information, you can access related documents from the following links:
•Cisco UCS Documentation Roadmap
•Cisco UCS Central Install and Upgrade Guides
This document is to be used in conjunction with the documents listed in the "Documentation and Support" section.
Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. To view a list of Cisco trademarks, go to this URL: www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. (1110R)
Any Internet Protocol (IP) addresses and phone numbers used in this document are not intended to be actual addresses and phone numbers. Any examples, command display output, network topology diagrams, and other figures included in the document are shown for illustrative purposes only. Any use of actual IP addresses or phone numbers in illustrative content is unintentional and coincidental.
© 2013 Cisco Systems, Inc. All rights reserved.


text:
Intel IT proof of concept presentation provides details on the deployment of Intel® Atom™ processor-based tablets with Windows* 8 at Intel.
Intel IT's Cathy Spence discuss their developer training for cloud aware applications.
Meet the new Intel CIO Kim Stevenson. Find out what attracted her to an IT career, her top IT priorities and how she plans to keep Intel successful.
Presentation: Intel conducts a crowdsourcing activity with employees, discovering innovative ideas for improving collaboration within the company.
White Paper: Intel IT optimizes PC delivery with prepared data, settings, and apps, improving employee and technician productivity and experience.
More capable and powerful devices can provide numerous benefits, even when accessing cloud-based services.
Intel IT compared Intel® Distribution for Apache Hadoop* with others and found that Intel Distribution offers significant advantages over the others.
Intel IT enhanced the Intel® Setup and Configuration Software tool, creating an agile configuration & maintenance environment for our mobile systems.
Switching to FCoE using converged network adapters yielded more than 50% reduction in network costs per server rack.
Learn how Intel IT's data center strategy improves the quality, velocity, and efficiency of our business services to create a competitive advantage.


text:
Professor Christopher Serkin was interviewed at length on the WNYC radio public affairs program, The Brian Lehrer Show, on Monday, September 28. The topic was eminent domain, the power of the government to take property, and its usage in New York City, including in Brooklyn's Atlantic Yards. Listen to Professor Serkin's interview.
Read the latest issue of BLS LawNotes


text:
Isn't this getting interesting. The Los Angeles Lakers have evidently decided to inject some drama into the regular season not by making a charge at the Cleveland Cavaliers for the NBA's best record, but by letting teams lurking behind them creep up in the standings. With their latest flop, a 94 to 96 loss to the Orlando Magic this afternoon, the Lakers are only two games ahead of Orlando and three ahead of the surging Dallas Mavericks. Hey, so long as every single issue gets ironed out in time to win a 2-7 series over the Thunder, it's all good, right?
A three-game East Coast road trip is now in the books as a three-game losing streak. As you'll hear or read 20 times between now and whenever the Lakers feel like winning another game, it's the first three-game skid of the Pau Gasol era. That's a mildly interesting footnote. The real story here is that the Lakers are now a pretty ordinary 17-13 on the road. Last year their road record was 29-12. For those whose eyes glaze over numbers, here's another way to put it: the Lakers have already lost more road games than they did all of last season. Who needs home-court advantage?
Today in Orlando, the Laker offense wasn't up to the job. The defense wasn't sensational. There were a lot of problems containing Jameer Nelson pick-and-roll sets, way too much fouling and poor work on the defensive glass. But thanks to active hands and craftiness in drawing offensive fouls, the Lakers held the Magic to 1.08 points per possession, a bit less than Orlando's season average. In Orlando's building that merits a passing grade.
The Lakers even did a great job of holding onto the ball themselves. In six of the last seven games coming into today, the Lakers had coughed up the orange roundie on at least 16% of their possessions. Today the turnover rate fell below 10%. Good stuff. The passing wasn't as careless and shambolic as it's been recently, which was nice to see.
But the shooting... good Lord. As a team the Lakers had an Effective Field-Goal Percentage of 40%. That's poisonously bad. Kobe Bryant, Derek Fisher, Ron Artest and Jordan Farmar - four of their key perimeter shooters - combined to shoot 14 for 41 (34%) on two point shots and 4 for 15 (27%) on threes. Of the backcourt guys, only Shannon Brown (an EFG of 50%) found the hoop with acceptable regularity. For the three-game road trip, the Lakers shot 14 of 58 (24%) on three-point attempts.
This is not aberrant. The Lakers aren't a good shooting team. They're an average shooting team that's worse than average on threes. And this, to me, is where the "flip the switch" hypothesis starts to wobble. I get you can summon greater effort and intensity in the playoffs. You can defend harder, you can shorten your rotations, you can fight for rebounding position with more verve than you bring on an afternoon in early March. But how do you just decide to start making shots? Outside shooting isn't a function of effort. It's a function of being good at shooting.
Emptying ye olde notebook bullet-point style:
- Kobe had another great offensive burst late in the fourth and had an OK first quarter. In between there were plenty of forced jumpers and what I would generally criticize as poor decision-making. I'm all for calling out Kobe when he's breaking the Triangle to dial his own number, but in this instance I give him a pass. The Lakers just didn't have any other good offensive options. If no one else is making an open look, I'm not sure a long series of Kobe iso's is worth getting outraged over.
- For him, Fish played a decent game. Which is unfortunate, because his performance wasn't good in any overall, objective sense. Orlando generated a lot of points by having Nelson blow by Fish, causing the other Lakers to scramble on help D, and then swinging the ball around to the open man. Farmar wasn't much better at containing Jameer.
- Dwight Howard played only 32 minutes because of foul trouble, but the Lakers failed to exploit the opening. In the 16 minutes he was off the court, L.A. outscored Orlando by only five points. Marcin Gortat is a good reserve center, but the Lakers have to win that matchup decisively when he's on the floor.
- It might get lost in the outcome, but this was a decent bounce-back game from Pau. He didn't defend Howard as well as he did in the Finals, but he was adequate, and his scores off offensive rebounds were a key source of pointage. Quite visibly, he's frustrated with how he's being treated by the refs.
- Kobe and Matt Barnes appear to be good friends.
At this point, I'm not sure it's even appropriate to debate whether the Lakers can flip the switch. Right now, there is no switch. There's just a hole in the wall and some loose wires hanging out. The Lakers need to fix the circuitry, repair the drywall, shop for a switch at Home Depot, screw it in and then pay their past-due bills with SoCal Edison. Then, maybe, there will be time left to flip it, and we can all hope the whole building doesn't short out.
Poss. |
OReb Rate |
DReb Rate |
Lakers |
90 |
8 |
0.30 |
89 |
0.19 |
46 |
29 |
40 |
47 |
29 |
62 |
1.04 |
Magic |
89 |
22 |
0.53 |
72 |
0.33 |
45 |
33 |
47 |
53 |
38 |
71 |
1.08 |
Follow Dex on Twitter here.


text:
looking forward to watching puig play MLB like it's softball in 2014... trying to stretch singles into doubles, intentionally missing the cutoff man and throwing home instead, acting like a little b1tch and running into the catcher when he's thrown out by a mile, etc.
Yasiel Puig battling shoulder inflammation, put on limited throwing program
Los Angeles Dodgers outfielder Yasiel Puig has been put on a limited throwing program while he battles right-shoulder inflammation, Dodgers manager Don Mattingly said Thursday.
Mattingly said that the team believes it is the same problem that bothered Puig last season. He said that Puig threw too much on the first day of spring training.
"We don't think it's serious, but we need to find out," Mattingly said, according to MLB.com. He added that the move to the limited throwing program was only "precautionary."
The 23-year-old Puig stormed onto the scene last season, finishing second in National League Rookie of the Year voting while batting .319 with 19 homers and 42 RBI. He also had 11 stolen bases for the NL West-champion Dodgers.
JAFFE: AL East spring training preview >
It's nice to see the mentally ill are still allowed to participate here.
Puig is "breaking down already"? The Dodgers "will struggle to win 40 games"?
Mental illness is a horrible thing.
OK, he had a shoulder issue last season, so on his FIRST day of spring training, he throws too much. This is on the team as well as Speedy here...
I don't get why people love him.
He has talent, but he does not hit the cut off man, he is a bad base runner and a nut case.
said same crap about this guy last year. guy will be broken down and washed up by age 27-28.
dodgers suck
LOL breaking down already? This guy is a joke. I hope he knows Japanese, he's outta here by years end. This team will struggle to win 40 games. Its pathetic if you think about it.
Get SI's Latest
News, Features, and more info delivered daily!


text:
Those wonderful cold war years! Space age pop, easy listening, lounge, exotica, movie/tv themes, novelty hits and wacky propaganda!
BETTER SOUND QUALITY! - From the early classics (1955) through the CB Radio craze (1985)!
WWII Music & History on the Web! Swing with G.I. Jive!
Oldies 1950's 1960's and more
Radio Dismuke
Your link to the Hits & Misses of the 50's & 60's!
Blues, roots, soul and rock n roll, and not just the hits. Best selection of early 50's RnB anywhere. Throw in lots of doowop and New Orleans classics, some rockabilly, Brit invasion, 50's standards, brew it up, that's Oldies and Blues
Hit the road with truckin' & travellin' favorites blending alt.country, bluegrass, country rock, western swing, cowboy, outlaw & classic country by established stars & independent artists spanning six decades from around the world on a past editor's pick!
Swing,crooners,Perry,Frank,Dinah,Patti,Doris Nat,Plus hits from the 50&60s.
Toe-tappin' music spotlighting the Shuffle Era of Country Music (late 50s to early 70s), as well as the prime cuts from the best of today's Shufflemeisters & Western Swingers.
Presenting some of our favorite Old Time Radio programs. If you enjoyed Knotted Note Radio be sure to check out the same great shows here on this very station! Mystery, Horror, Detective, Thrillers, Sci-Fi, Westerns, And Much More! www.DramaticRadio.com
Wartime Tunes! WWII Big Band, Swing, and Authentic WWII News Radio Clips
Playing all your favorite doo wop records from the '50s and early '60s, plus all the obscure doo wops you've never heard before!
SEX-E sixties. From 1960 to 1969. The best songs and the forgotten songs of the SIXTIES. Animals, Byrds, Cash, Iron Butterfly, rare live concert stuff, Movie & TV Themes. Check this site out and go back in time to the Sixties.
It's the stroke of midnight, and KIBM Internet Radio has opened Pandora's box, A faint WHISTLE can be heard....the SUSPENSE builds. What lies in the darkness of the box is your own fear and imagination.


text:
While two different words may have the same meaning for you, the SEs just see two different words, and look for a best match on your pages. You might, for example, use 'tiny', 'minute' and 'very small' interchangeably; but whatever you think, the SEs see three totally independent searches, and will deliver what you actually ask for - not necessarily what you want! Why would you have more than one spelling of 'widgets' anyway? [edited by: Receptional_Andy at 3:37 pm (utc) on Aug. 27, 2008]
I'm not sure I understand the problem. Using different keywords will inevitably get different results.
[edit reason] removed specifics [/edit]